Physicians > About NurAiD™II
NurAiD™II (MLC 901) is a compound based on natural extracts that helps patients recover faster and better from their stroke disabilities.
Recommended dosage per course of treatment is to take two capsules three times a day for three months.
The first results are usually observed as early as three to five weeks after treatment initiation and in most cases before two months, and we recommend three courses of the one-month treatment taken without interruption to achieve best results.
NurAiD™II has a very safe profile; therefore, patients who feel they continue to improve after three months can continue taking it for up to six months or longer.
NurAiD™II is most effective when taken daily during treatment. If you happen to forget to take your NurAiD™II capsules once, there’s no need to double up on NurAiD™II capsules the next time—just take the next capsules at your usual time. We recommend that you take your NurAiD™II capsules as part of a regular routine, as it will support more effective results.
NurAiD™II can be prescribed to patients suffering from a stroke and brain trauma injury:
NurAiD™II is marketed in France and Belgium as a food supplement and available for sale on this website and a few pharmacies in France and Belgium.
NeuroAiD™ creates a favorable environment to enhance neuroplasticity.
Specifically, NeuroAiD™ triggers the production of new neurons in the brain (neurogenesis) and favors connections between neurons by stimulating the formation of dendrites and synapses (neuroplasticity).
This process favors the formation of new functional neuronal circuits, which are keys to a fuller poststroke recovery. Changes in the brain materialize into more progress in neurological functions during rehabilitation. This neurorehabilitative activity of NeuroAiD™ was established in 2010 by a team of French scientists, and results were published in a peer-reviewed international journal.
Origins of NurAiD™II
Plants are a source of several medical treatments.
NurAiD™II has been launched after the CNRS team has proven that the two formulas, NeuroAiD™ (MLC 601) and NurAiD™II (MLC 901), are pharmacological equivalent. The results obtained were published in Neuropharmacology,¹ in February 2010.